Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Given Consensus Rating of "Buy" by Brokerages

Friday, April 16, 2021 | MarketBeat

Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) has received an average recommendation of "Buy" from the seven brokerages that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $62.00.

FMTX has been the subject of several research reports. Oppenheimer restated a "buy" rating on shares of Forma Therapeutics in a research report on Thursday, March 18th. HC Wainwright raised their price target on shares of Forma Therapeutics from $53.00 to $55.00 and gave the company a "buy" rating in a report on Wednesday, March 31st. Finally, Zacks Investment Research downgraded Forma Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, February 18th.

FMTX stock traded down $1.78 during midday trading on Friday, reaching $26.55. 11,978 shares of the company's stock traded hands, compared to its average volume of 474,620. The company has a 50-day simple moving average of $31.54 and a two-hundred day simple moving average of $39.10. Forma Therapeutics has a 1-year low of $22.51 and a 1-year high of $56.33.

Forma Therapeutics (NASDAQ:FMTX) last announced its earnings results on Monday, March 29th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.12. On average, equities analysts expect that Forma Therapeutics will post -4.09 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Penserra Capital Management LLC acquired a new position in shares of Forma Therapeutics in the 4th quarter valued at $32,000. Pacer Advisors Inc. acquired a new position in Forma Therapeutics in the fourth quarter valued at about $42,000. Morgan Stanley boosted its holdings in Forma Therapeutics by 13,970.8% during the third quarter. Morgan Stanley now owns 3,377 shares of the company's stock worth $168,000 after buying an additional 3,353 shares during the last quarter. Strs Ohio bought a new position in Forma Therapeutics during the third quarter worth about $199,000. Finally, Citigroup Inc. increased its stake in shares of Forma Therapeutics by 516.7% in the 4th quarter. Citigroup Inc. now owns 4,773 shares of the company's stock valued at $167,000 after acquiring an additional 3,999 shares during the last quarter. 67.28% of the stock is owned by hedge funds and other institutional investors.

About Forma Therapeutics

Forma Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer.

Read More: The basics of gap trading strategies

Analyst Recommendations for Forma Therapeutics (NASDAQ:FMTX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: Why is total return important?



7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future

When you say the Internet of Things (IoT) you may get different responses. I like to think of it broadly as being about connection. It’s about devices that can connect with each other, and with the internet. And this provides users with the solutions that are making our lives more convenient.

The most basic, and ubiquitous, example of an IoT device is the smartphone that many of us have with us at all times. But think about what that has led to. Home assistants, security cameras, fitness apps, and so much more are all enabled by the internet of things.

IoT took on even more importance in the pandemic as businesses had to find a way to ensure the security and viability of their networks even as their employees were scattered remotely. This created demand for edge and cloud computing solutions that are also facilitated by the internet of things.

And yes, this is just the start. The need for more and more data is powering demand for IoT solution in areas such as autonomous vehicles.

But the good news is that this is an area that is still very much in its growth phase. And that means there is no lack of companies that you can find to trade in this sector. To help you get started, we’ve put together this special presentation that highlights seven such companies and the reasons why we believe they merit adding to your portfolio.

View the "7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future".


Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.